Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To determine the effect of severe renal impairment on the pharmacokinetic profile of
teriflunomide administered as a single 14 mg dose as compared to healthy subjects
Secondary Objective:
- To assess the tolerability of teriflunomide administered as a single 14 mg dose in subjects
with severe renal impairment compared to subjects with normal renal function.